tin mesoporphyrin

Phase 2Small molecule

NNational Center for Research Resources (NCRR)

tin mesoporphyrin is one of 18 small molecule programs targeting Hyperbilirubinemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperbilirubinemiaActive, not recruiting

HyperbilirubinemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Hyperbilirubinemia

#DrugCompanyPhaseTrials

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Approved

3 2

Immunoglobulin

Sanofi

Approved

1 3

Verazinc

FFakultas Kedokteran Universitas Indonesia

Phase 2

2 4

Zinc Gluconate

Johnson & Johnson

Phase 2

1 5

Gemzar

Johnson & Johnson

Phase 1

1 6

Abraxane

Bristol-Myers Squibb

Phase 1

1 7

Medrol

Pfizer

Preclinical

1 8

Tricor

JJagotec

Preclinical

2 9

Stannsoporfin

IInfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

Phase 2

1 10

Reyataz

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperbilirubinemia2 trials

Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00004382·80 enrolled

Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00004381

Acute Porphyria2 trials

Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria

Completed·NNational Center for Research Resources (NCRR)·Phase 1/2·NCT00004789·59 enrolled

Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004396·32 enrolled

Acute1 trial

Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria

Completed·NNational Center for Research Resources (NCRR)·Phase 1·NCT00004398·24 enrolled

Prevention1 trial

Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria

Completed·NNational Center for Research Resources (NCRR)·Phase 1·NCT00004397·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for tin mesoporphyrin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tin mesoporphyrin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tin mesoporphyrin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Center for Research Resources (NCRR) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Center for Research Resources (NCRR)

tin mesoporphyrin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperbilirubinemia2 trials

Acute Porphyria2 trials

Acute1 trial

Prevention1 trial

References

Drug Info

Quick Facts

Related News